Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have been given an average rating of "Buy" by the twenty-two analysts that are currently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and fourteen have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $161.31.

A number of analysts have issued reports on the stock. The Goldman Sachs Group cut their price objective on shares of CRISPR Therapeutics from $193.00 to $189.00 and set a "neutral" rating for the company in a report on Wednesday, February 17th. TheStreet cut shares of CRISPR Therapeutics from a "c-" rating to a "d" rating in a research report on Wednesday, March 10th. Evercore ISI upgraded shares of CRISPR Therapeutics to an "outperform" rating in a research report on Thursday, May 13th. Chardan Capital boosted their target price on shares of CRISPR Therapeutics from $166.00 to $175.00 and gave the company a "buy" rating in a research report on Wednesday, February 17th. Finally, Oppenheimer boosted their target price on shares of CRISPR Therapeutics from $165.00 to $187.00 and gave the company an "outperform" rating in a research report on Wednesday, February 17th.

NASDAQ CRSP opened at $113.29 on Monday. The company has a market cap of $8.58 billion, a PE ratio of -20.12 and a beta of 2.26. The company has a 50 day moving average price of $117.51. CRISPR Therapeutics has a 52 week low of $58.02 and a 52 week high of $220.20.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, April 26th. The company reported ($1.51) EPS for the quarter, missing analysts' consensus estimates of ($1.47) by ($0.04). CRISPR Therapeutics had a negative net margin of 35,630.97% and a negative return on equity of 27.42%. As a group, sell-side analysts expect that CRISPR Therapeutics will post 0.66 earnings per share for the current year.

In other CRISPR Therapeutics news, Director Bradley J. Phd Bolzon sold 30,374 shares of the business's stock in a transaction that occurred on Monday, March 22nd. The shares were sold at an average price of $132.37, for a total transaction of $4,020,606.38. Following the sale, the director now directly owns 57,149 shares of the company's stock, valued at approximately $7,564,813.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 21.40% of the company's stock.

Several large investors have recently made changes to their positions in CRSP. Abundance Wealth Counselors acquired a new position in shares of CRISPR Therapeutics in the 1st quarter valued at about $26,000. RMR Wealth Builders bought a new stake in CRISPR Therapeutics in the 1st quarter valued at about $29,000. Ameritas Investment Company LLC bought a new stake in CRISPR Therapeutics in the 1st quarter valued at about $29,000. Trustcore Financial Services LLC bought a new stake in CRISPR Therapeutics in the 4th quarter valued at about $31,000. Finally, Eudaimonia Partners LLC bought a new stake in CRISPR Therapeutics during the 1st quarter worth approximately $31,000. 55.60% of the stock is currently owned by institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.

See Also: What is required to own or exchange cryptocurrency?

Analyst Recommendations for CRISPR Therapeutics (NASDAQ:CRSP)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: Is it Safe to Invest in Commodities?

7 Stocks to Buy Now and Avoid a Summer Swoon

Summer is generally a quiet time in the markets. Institutional investors, generally speaking, take some time away. In fact, that’s where the idiom “Sell in May and Go Away” comes from.

But quiet doesn’t mean uneventful. The world still moves along even in the lazy months of summer. And at the moment, there are two conflicting views driving the market.

One is the fear that everything’s a bubble that is just about to burst. We don’t recommend you get out of stocks, but let’s face it, things are more than just a little frothy.

But there’s another view summarized by the acronym, YOLO (as in You Only Live Once). And these investors are committed to keeping the markets going higher. Even if it means going “all in” (whatever that means to them) on risky asset classes like NFTs or Dogecoin.

We sincerely hope you take time to recharge (whatever that means to you) this summer. Whatever your personal beliefs, the reopening of our economy is a moment that deserves to be celebrated by all of us. But before you do, we recommend that you take a peek at these seven stocks that you can consider adding to your portfolio before you check out for the summer. These are likely to get as hot as a firecracker on the Fourth of July and should have you smiling when the summer ends.

View the "7 Stocks to Buy Now and Avoid a Summer Swoon".



Source link